Stroke and transient ischemic attack in the long-term care setting: Patient characteristics, medication treatment, and length of stay

Consultant Pharmacist

Volumn 26, Issue 3, 2011, Pages 170-181

  Meyers, Juliana L ^a   Davis, Keith L ^a   Yu, Yanni F ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Long term care; Stroke; Stroke prevention; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CLOPIDOGREL; TICLOPIDINE; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; COMORBIDITY; DEMOGRAPHY; FEMALE; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MEMORY DISORDER; PRIVATE HEALTH INSURANCE; RESIDENTIAL AREA; RETROSPECTIVE STUDY; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK; DRUG ADMINISTRATION; FACTUAL DATABASE; MIDDLE AGED; STATISTICS; TIME;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LENGTH OF STAY; LONG-TERM CARE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; STROKE; TICLOPIDINE; TIME FACTORS;

EID: 79955788626     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2011.170     Document Type: Article

References (22)

1. Lloyd-Jones D, Adams RJ, Brown TM et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Health and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010;121:46-215.
2. Easton JD, Saver JL, Albers GW et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke 2009;40:2276-93.
3. Hankey GJ. Impact of treatment of people with transient ischemic attack on stroke and incidence and public health. Cerebrovasc Dis 1996; 6 suppl 1:26-33.
4. Lisabeth LD, Ireland JK, Risser JMH et al. Stroke risk after transient ischemic attack in a population-based setting. Stroke 2004;35:1842-6. (Pubitemid 38971862)
5. Kleindorfer D. Panagos P, Pancioli A et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005;36:720-3.
6. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischemic attack or minor stroke: implications for public education and organization of services. BMJ 2004;328:326.
7. Johnston SC, Fayad PB, Gorelick PB et al. Prevelance and knowledge of transient ischemic attack among US adults. Neurology 2003;60:1429-34. (Pubitemid 36554801)
8. Centers for Disease Control and Prevention. National Center for Health Statistics faststats: leading causes of death. 2009. Available at http://www.cdc.gov/nchs/FASTATS/lcod.htm. Accessed June 10, 2010.
9. DeFrances CJ, Lucas CA, Buie VC et al. 2006 National Health Statistics Reports, No. 5. National Hospital Discharge Survey. Hyatsville, MD: National Center for Health Statistics; 2008.
10. Lee A, Huber J, Stason W. Poststroke rehabilitation in older Americans: the Medicare experience. Med Care 1996;34:811-25. (Pubitemid 126433273)
11. Brown DL, Boden-Albala B, Langa KM et al. Projected costs of ischemic stroke in the United States. Neurology 2006;67:1390-5. (Pubitemid 44632062)
12. Albers GW, Amarenco P, Easton JD et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008;133:630-669.
13. Quilliam BJ, Lapane KL. Clinical correlates and drug treatment of residents with stroke in long-term care. Stroke 2001;32:1385-93.
14. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60.
15. Aubert R, Epstein RS, Teagarden JR et al. Proton pump inhibitor effects on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study [abstract]. Circulation 2008;118:815. Abstract No. 2998.
16. Dunn SP, Macaulay TE, Brennan DM et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial [abstract]. Circulation 2008;118:S815. Abstract No. 2999.
17. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-8.
18. American Heart Association. Heart disease and stroke facts, 2004 update. Available at http://www.americanheart.org/downloadable/heart/ 1079736729696HDSStats2004UpdateREV3-19-04.pdf. Accessed June 10, 2010.
19. American Medical Directors Association. Clinical practice guideline: stroke management and prevention in the long-term care setting. 2005.
20. Moroney JT, Bagiella E, Tatemichi TK et al. Dementia after stroke increases the risk of long-term stroke recurrence. Neurology 1997; 48:1317-25. (Pubitemid 27240556)
21. Monette J, Gurwitz JH, Rochon PA et al. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997;45:1060-5. (Pubitemid 27377551)
22. Leibson C. Clinical correlates and drug treatment of residents with stroke in long-term care [editorial comment]. Stroke 2001;32:1385-93.